

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Finerenone for treating chronic kidney disease in people with type 2 diabetes
ID3773

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bayer (finerenone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency • Diabetes Research and Wellness Foundation • Diabetes UK • Heart UK • InDependent Diabetes Trust • Kidney Care UK • Kidney Research UK • National Kidney Federation • Network of Sikh Organisations • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • Association of Renal Technologists • At the 4-Front • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Association of Endocrine and Thyroid Nurses • British Association of Urological Nurses • British Geriatrics Society • British Heart Foundation 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (dapagliflozin) • Boehringer Ingelheim (empagliflozin) • Merck Sharp & Dohme (ertugliflozin) • Napp Pharmaceuticals (canagliflozin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney and Transplant Group • Cochrane Metabolic & Endocrine Disorders Group • Genomics England

Provisional stakeholder list for the technology appraisal of finerenone for treating chronic kidney disease in people with type 2 diabetes ID3773 Issue date: March 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Renal Society • National Metabolic Biochemistry Network • Primary Care Diabetes Society • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • Society for Endocrinology • TREND UK • UK Clinical Pharmacy Association • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Eastern Cheshire CCG • NHS England • NHS South West Lincolnshire CCG • Welsh Government 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research • Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.